Pharmacokinetics of ofloxacin in drug-resistant tuberculosis

Journal of the Medical Association of Thailand

Volumn 86, Issue 8, 2003, Pages 781-788

  Chulavatnatol, Suvatna ^a   Chierakul, Nitipatana ^b   Chindavijak, Busba ^a   Klomsawat, Duangrat ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Drug Resistant Tuberculosis; Ofloxacin; Pharmacokinetics

Indexed keywords

AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; ETHAMBUTOL; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG ELIMINATION; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

ADULT; ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG THERAPY, COMBINATION; HUMANS; MIDDLE AGED; OFLOXACIN; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 0141478755     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs 2001; 61: 9-18.
2. Telenti A, Iseman MD. Drug-resistant tuberculosis: What do we do now? Drugs 2000; 59: 171-9.
3. Kaplan JA, Krieff DM. Quinolones for the treatment and prophylaxis of tuberculosis. Ann Pharmacother 1996; 30: 1020-2.
4. Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 1997; 25: 1213-21.
5. Paton JH, Reeves DS. Fluoroquinolone antibiotics: Microbiology, pharmacokinetics and clinical use. Drugs 1998; 36: 193-228.
6. Garcia-Rodriguez JA, Gomez Garcia AC. In vitro activities of quinolones against mycobacteria. J Antimicrob Chemother 1993; 32: 797-808.
7. Todd PA, Faulds D. Ofloxacin: A reappraisal of its antimicrobial activity, pharmacology and therapeutic use. Drugs 1991; 42: 825-76.
8. Jacobs MR. Activity of quinolones against Mycobacteria. Drugs 1999; 58 (Suppl 2): 19-22.
9. Yew WW, Kwan SY, Ma WK, et al. In vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiple resistant pulmonary tuberculosis. J Antimicrob Chemother 1990; 26: 227-36.
10. Berning SE, Madsen L, Iseman MD, et al. Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. Am J Respir Crit Care Med 1995; 151: 2006-9.
11. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784-91.
12. Onrust SV, Lamb HM, Barman Balfour JA. Ofloxacin: A reappraisal of its use in the management of genitourinary tract infections. Drugs 1998; 56: 895-928.
13. Lode H, Hoffken G, Olschewski P, et al. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother 1987; 31: 1338-42.
14. Perea EJ. Ofloxacin concentrations in tissues involved in respiratory tract infections. J Antimicrob Chemother 1990; 26 (Suppl D): 55-60.
15. Kohno S, Koga H, Kaku M, et al. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest 1992; 102: 1815-8.
16. Yew WW, Chan CR, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000; 117: 51.
17. Maranetra KN. Quinolones and multidrug-resistant tuberculosis. Chemotherapy 1999; 45 (Suppl 2): 12-8.
18. Chulavatnatol S, Chindavijak B, Vibhagool A, et al. Pharmacokinetics of levofloxacin in healthy Thai male volunteers. J Med Assoc Thai 1999; 82: 1127-34.
19. Chierakul N, Klomsawat D, Chulavatnatol S, et al. Intrapulmonary pharmacokinetics of ofloxacin in drug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 278-82.
20. th ed. Stamford: Appleton & Lange, 1999: 66-8.
21. Wolfson JS, Hooper DC. Comparative pharmacokinetics of ofloxacin and ciprofloxacin. Am J Med 1989; 87 (Suppl 6C): 31S-6S.
22. Flor S. Pharmacokinetics of ofloxacin: An overview. Am J Med 1989; 87 (Suppl 6C): 24S-30S.
23. Yew WW, Cheung SW, Chau CH, et al. Serum pharmacokinetics of antimycobacterial drugs in patients with multidrug-resistant tuberculosis during therapy. Int J Clin Pharm Res 1999; 19: 65-71.
24. Lockley MR, Wise R, Dent J. The pharmacokinetics and tissue penetration of ofloxacin. J Antimicrob Chemother 1984; 14: 647-52.
25. Wright DH, Brown GH, Peterson ML, et al. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000; 46: 669-83.
26. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-83.
27. Crofton J, Chaulet P, Maher D. Guidelines for the management of drug-resistant tuberculosis. Geneva: World Health Organization, 1997: 27.
28. Ruiz-Serrano MJ, Alcala L, Martinez L, et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob Agents Chemother 2000; 44: 2567-8.
29. Pracharktam R, Angkananukool K, Vibhagool A. In vitro susceptibility testing of levofloxacin and ofloxacin by microtiter plate alamar blue against multidrug and non multidrug resistant Mycobacterium tuberculosis in Thailand. J Med Assoc Thai 2001; 84: 1241-5.